Latest / The SPY Trader / Market Waves: Navigating Highs, Lows, and Market Moves

Transcript

Market Waves: Navigating Highs, Lows, and Market Moves · The SPY Trader

• 0:00
  Welcome to the latest episode of Spy Trader,
• 0:03
  your goto podcast for everything S&P 500!
• 0:06
  I'm your host,
• 0:07
  Chuck Financefella,
• 0:08
  here to guide you through the highs and lows of the market,
• 0:13
  And speaking of highs and lows,
• 0:15
  what did the stock market's therapist say?
• 0:18
  "Let's explore these highs and lows,
• 0:21
  " It's October 16th,
• 0:22
  12:00 PM,
• 0:23
  and we've got a packed episode for you,
• 0:26
  Let's dive right in!
• 0:28
  In today’s main story,
• 0:30
  we’re focusing on Johnson & Johnson's (JNJ) thirdquarter results,
• 0:33
  The healthcare giant reported an adjusted EPS of $2,
• 0:37
  42,
• 0:37
  beating estimates but representing a 9% drop from last year,
• 0:42
  Their sales jumped to $22,
• 0:44
  47 billion,
• 0:45
  a 5,
• 0:45
  2% increase that surpassed expectations,
• 0:47
  They've adjusted their fullyear guidance thanks to the acquisition of VWave,
• 0:52
  signaling some optimism,
• 0:53
  The analysis here is twofold,
• 0:55
  On the upside,
• 0:56
  J&J's pharmaceutical segment,
• 0:58
  particularly oncology drugs like Darzalex and Carvykti,
• 1:01
  shows robust growth potential,
• 1:02
  The recent approval of Rybrevant for lung cancer should also boost their sales,
• 1:08
  However,
• 1:08
  challenges loom in their MedTech division due to procurement pressures in markets like China,
• 1:14
  and let's not forget the elephant in the room: ongoing talc litigation,
• 1:19
  What does this mean for the S&P 500?
• 1:22
  Well,
• 1:22
  J&J is a big player in the index,
• 1:26
  especially within the healthcare sector,
• 1:28
  Their performance can set the tone for sentiment in the industry,
• 1:32
  The mixed signals—strong pharma growth vs,
• 1:35
  MedTech struggles and litigation uncertainties—suggest a cautious stance from investors,
• 1:39
  This could mean that if you're heavily invested in healthcare,
• 1:43
  you might want to keep a close eye on these developments,
• 1:48
  Now,
• 1:48
  let’s switch gears to ASML Holding's recent announcement,
• 1:51
  After reducing their 2025 sales guidance,
• 1:54
  a notable ripple effect was felt across the Nasdaq100,
• 1:58
  particularly in the semiconductor sector,
• 2:00
  This resulted in the largest singleday drop in open interest for Nasdaq100 futures this year—a whopping $5,
• 2:07
  7 billion!
• 2:08
  There's clear apprehension regarding future tech stock performance,
• 2:11
  Turning back to the S&P 500,
• 2:13
  this cautionary tale underscores the interconnectedness of sectors,
• 2:17
  While not directly an S&P 500 story,
• 2:19
  tech's significant role in the index means that bearish sentiment can spill over,
• 2:25
  affecting broader market stability,
• 2:27
  As for trading recommendations,
• 2:28
  given J&J’s outlook,
• 2:29
  a strong case could be made for honing in on the pharma side of healthcare if you’re looking to add to your portfolio,
• 2:39
  Cancer treatments and drugs with FDA approval tend to show resilience and potential for steady growth,
• 2:45
  Meanwhile,
• 2:46
  remain agile and circumspect with broader exposure in tech due to potential volatility sparked by lower guidance from heavyweights like ASML,
• 2:55
  Sector rotation into safer zones like consumer staples or utilities might be prudent until things stabilize in tech,
• 3:02
  As we wrap up,
• 3:04
  remember that market dynamics are always shifting,
• 3:07
  so staying informed and adaptable is key,
• 3:09
  That's it for now on Spy Trader with me,
• 3:13
  Chuck Financefella,
• 3:14
  Stay tuned for more updates and remember to subscribe for your regular dose of market insights!